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ABSTRACT   
Background: Fungal infections are still a relevant challenge for clinicians involved 
in the cure of patients with cancer. We retrospectively reviewed charts of 
hospitalized patients with hematological malignancies (HMs), in which a 
documented fungemia was diagnosed between January 2011 and December 
2015 at 28 adult and 6 pediatric Italian Hematology Departments.  
 
Methods: During the study period we recorded 215 fungal blood stream 
infections (BSI). Microbiological analyses documented that BSI was due to molds 
in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp 
identified in 174 patients (81%).  
 
Results: Mortality rates were 70% and 39% for mold and yeast infections, 
respectively. Infection was the main cause of death in 53% of the mold and 18% 
of the yeast groups. At the multivariate analysis, ECOG ≥2 and septic shock were 
significantly associated with increased mortality, and removal of CVC survival 
was found to be protective. When considering patients with candidemia only, 
ECOG >2 and removal of CVC were statistically associated with overall mortality.  
 
Conclusions: Although candidemia represents a group of BSI with a good 
prognosis, its risk factors largely overlap with those identified for all fungemias, 
even though the candidemia-related mortality is lower when compared to other 
fungal BSI. Management of fungal BSI is still a complex issue, in which both 
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patients and disease characteristics should be focused to address a personalized 
approach.  
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INTRODUCTION 
Fungal infections are still a relevant challenge for clinicians involved in the cure 
of patients with cancer. On one hand, high dose chemotherapy, mucosal barriers 
damage, impairment of immune system due to underlying malignancy and its 
treatment are known risk factors that are difficult to overcome. On the other 
hand, in this setting the wide use of antimicrobic prophylaxis and therapy as well 
as the preemptive antifungal treatment may have contributed to the 
epidemiology of identified isolates in this setting of patients.  
In the last years, several studies have reported on prevalence of invasive fungal 
infections (IFI), defined as involvement of lung, central nervous system, sinuses 
and bloodstream infections (BSI). Since 2004, overall incidence of candidemia 
has been almost stable around 1.4% among patients with hematological 
malignancies (HM)1. In 2015, Cornely et al reported an overall incidence of 
0.42% among 27195 hematological patients admitted to hospital, which has 
grown up to 1.46% in HSCT recipients2.  
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Reports of non-Candida fungemia are rare. In a multicenter study Nucci et al 
reported 11% of BSI due to Fusarium spp among 61 hematopoietic stem cell 
transplant recipients followed from 1985 through 20013.  
Fungemia related death is a complex issue: the underlying malignancy itself play 
a paramount role in the development of IFI. The clinical suspicion and the 
prompt start of antifungal therapy may be the most effective intervention for 
improving patient outcomes in some cases. 
We focused on epidemiology of fungal BSI in patients affected by either myeloid 
or lymphoid HM admitted over the past five years to 34 Italian hematology 
centers participating to the SEIFEM consortium.  
 
MATERIALS AND METHODS 
Study design  
We retrospectively reviewed charts of hospitalized patients with HM in which a 
documented fungemia was diagnosed between January 2011 and December 
2015 at 34 adult and pediatric Italian Hematology Departments. Demographic, 
hematological and microbiological data were registered in an electronic form. In 
particular, all participating centers collected information about age, sex, 
performance status according to ECOG scale, concomitant chronic diseases 
(chronic renal disease, diabetes mellitus, chronic obstructive pulmonary 
disease), previous surgical procedures, type of HM, last chemotherapy 
administration, type of transplantation, use and duration of steroids, absolute 
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neutrophil count and recovery of neutropenia, barrier damage following 
treatment (mucositis, parental nutrition), insertion and removal of central 
venous catheter (CVC), type of antifungal prophylaxis, presenting symptoms of 
fungemia (fever, gastro-intestinal or respiratory, septic shock) and parenchymal 
dissemination, antifungal treatment. The diagnostic work up of patients with 
fever was performed according to local clinical practice and similarly among the 
centers: rectal swabs at admission, blood culture at spiking fever, galactomannan 
assay twice weekly, chest X-ray at onset of fever, chest CT scan after 5-7 days of 
persistence of fever. According to clinical symptoms and laboratory findings, 
patients included in the study underwent additional radiological exams (brain 
and sinuses CT scan, abdominal ultrasound), bronchoalveolar lavage and fundus 
evaluation according to good clinical practice.  
Outcome of patients was evaluated at 30 days from detection of fungemia, as the 
minimum follow-up available for all patients. Our research has been conducted 
following Helsinki declaration principles and approved by local ethical 
committee.  
 
Definition 
Fungemia was defined as at least one blood culture positive for a yeast or mold 
strain, associated to symptoms of infection referable to the fungal pathogens (i.e. 
fever, hypotension, respiratory distress, gastrointestinal symptoms). 
Breakthrough fungemia was defined by at least one positive blood culture 
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associated with above-mentioned symptoms occurring during systemic 
antifungal prophylaxis treatment started within 3 days4. Fungemia was 
considered as CVC-related if the isolated strain grew from CVC drawn blood 
faster than peripheral blood (with a differential time to positivity of 2 hours), or 
from a removed CVC-tip5. Severe neutropenia is defined as an absolute 
neutrophil count (ANC) less than 500 cells/mm3. Recovery of neutropenia is 
defined as ANC stably over 1000 cells/mm3. Bronchoscopy and biopsy proved 
lung and liver/spleen involvement.  
Empirical antifungal therapy was defined as treatment started before 
microbiological identification of fungal isolate. Clinical efficacy of antifungal 
treatment was defined as complete resolution of clinical signs and symptoms of 
fungemia2.  
Survival was evaluated at 30 days from the microbiological isolation of fungi: 
death was attributed to infection, HM or other complication whenever possible. 
Fungi attributable mortality was defined as a death in patients with 
microbiological, histological, or clinical evidence of active fungal infection and no 
other clearly identifiable causes of death6. 
 
Statistical analysis 
The aim of the study was to show clinical characteristics of patients and the 
prevalence of well-known risk factors associated to fungal disease in our 
population, identifying parameters predictive of outcome. Results are expressed 
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as means ± SD or medians (IQR) (continuous variables) or as percentages of the 
group from which they were derived (categorical variables). The Student t test 
and Mann-Whitney U test were used to compare normally and non-normally 
distributed continuous variables, respectively. Categorical variables were 
evaluated with the chi-square or two-tailed Fisher exact test. ORs and 95% CIs 
were calculated for all associations that emerged; a P value of <0.05 was 
considered significant. Multivariate logistic regression analysis was used to 
identify independent risk factors for 14-day mortality. Variables emerging from 
univariate analysis with P values of <0.1 were included in the multivariate model 
in a backward stepwise manner. All statistical analyses were performed with the 
Intercooled Stata program, version 11. 
 
RESULTS 
During the study period we recorded 215 fungal BSI among 199 adults and 16 
pediatric patients with HM. Demographic and clinical characteristics according to 
the isolate species are reported in Table 1. A more detailed distribution of all 
isolated strains is showed in Table 2.  
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Isolated strains  
Microbiological evaluation revealed that BSI was due to molds in 17 patients 
(8%) and yeasts in 198 patients (92%). Among 17 molds, 11 (65%) were 
Fusarium spp, 3 (17%) were Aspergillus fumigatus, and 1 for each of the 
remaining isolates Mucor spp, Trichoderma viridae and Scedosporium 
apiospermium (6%). Candida spp was identified in 174 patients (81%): Candida 
albicans accounted for 58 (33%) isolated strains, while the other Candida strains 
were distributed as follow: C. tropicalis 17 (10%), C. glabrata 24 (14%), C. 
parapsilosis 38 (22%), C. krusei 17 (10%), and other Candida 20 (11%). Among 
24 other yeasts, 10 (42%) were Geotrichum spp, 6 (25%) were Rhodotorula spp, 4 
(17%) were Trichosporon spp, 3 (12%) were Saprochaeta spp, and Saccaromyces 
was 1 (4%).  
 
Epidemiological distribution 
Molds BSI 
Of the 17 patients with mold BSI, 13 were males (76%) and 13 (76%) were <60-
year-old. Overall, the median age was 52 years (range 8- 75). Fifteen patients 
(88%) had a central venous catheter (CVC), 8 of which were centrally inserted. 
Positive blood cultures were detected from CVC in 5 (29%) and from peripheral 
blood in 12 patients (71%).  
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Use of parental nutrition and mucositis were present in 7 (41%) and 4 (23%) of 
patients respectively. Severe neutropenia was reported in 15 patients (88%), and 
only 2 (13%) recovered during antifungal treatment. Half of patients received 
steroids within 30 days before the onset of infections; none underwent previous 
surgical procedure. ECOG was >2 in 7 (41%) patients. 
All but two patients received antifungal prophylaxis as following: 4 (27%) 
fluconazole and 11 (73%) mold active agents (posaconazole 6, itraconazole 3, 
voriconazole 2).  All patients experienced fever, 2 had gastro-intestinal (GI) 
symptoms (12%); 5 (29%) respiratory symptoms and 3 (18%) septic shock. 
Organ dissemination (2 skin, 3 lung and 2 sinus) was documented in 6 patients. 
At the time of infection, 70% of patients had refractory or relapsed disease and 
30% untreated disease.  
 
Yeasts non-Candida BSI 
In 24 patients BSI was due to a yeast other than Candida: they were almost 
equally distributed among female (54%) and male (46%), with a median age of 
61 years (range 21-74 years). A CVC was present in 18 patients (75%), centrally 
inserted in 8 (33%): positive blood cultures were detected from CVC in 9 (37%), 
peripheral blood in 11 (46%) and both CVC and peripheral blood in 4 (17%) 
patients. 
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Use of parenteral nutrition and a previous surgical procedure were reported in 9 
(37%) and 2 patients (8%) respectively. Moreover, mucositis was reported in 9 
(37%) patients and 16 (67%) assumed steroids within 30 days before the onset 
of infection. Severe neutropenia was reported in 23 (96%) patients, only 5 of 
which (22%) recovered during antifungal treatment. ECOG was >2 in 9 (37%) 
patients. 
Fourteen patients (58%) received antifungal prophylaxis: 3 (21%) with 
fluconazole and 11 (79%) with mold active agents. Symptoms of fungemia 
included fever in all patients, GI involvement in 7 (29%), respiratory symptoms 
in 2 (8%) and septic shock in 2 (8%). Organ dissemination occurred in 3 (12%) 
patients (1 skin, 1 lung and 1 liver). At the time of infection, underlying 
malignancy was active in 20 (87%) of patients: 11 (55%) had refractory or 
relapsed disease and 9 (45%) untreated disease. Four patients were in complete 
remission.  
 
Candidemia 
In 174 patients BSI was due to Candida spp: they were almost equally distributed 
among male (55%) and female (45%), with a median age of 56 years (range 40-
66 years). Almost all patients had a CVC (168, 96%), centrally inserted in 99 
(64%): positive blood cultures were detected from CVC in 69 (40%), peripheral 
blood in 61 (35%) and both CVC and peripheral blood in 44 (25%) patients. 
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Use of parental nutrition and a previous surgical procedure were present in 71 
(41%) and 27 (15%) respectively. Moreover, mucositis was reported in 57 
(33%) of patients, and 90 (52%) assumed steroids within 30 days before the 
onset of infections. Severe neutropenia was reported in 134 (77%) patients, 47 
(35%) of which recovered during antifungal treatment. ECOG was >2 in 71 
(41%) patients. Twenty-one patients (12%) suffered from chronic kidney disease 
and 6 (3%) from chronic obstructive pulmonary disease.  
Eighty patients (46%) received antifungal prophylaxis: 36 (21%) with 
fluconazole and 44 (25%) with mold active agents. Fever was present in 171 
(98%) patients, gastro-intestinal (GI) involvement in 56 (32%), respiratory 
symptoms in 43 (25%) and septic shock in 24 (14%). Organ dissemination (7 
skin, 3 lung, 3 brain and 1 spleen) occurred in 12 patients (7%). At the time of 
infection, underlying malignancy was active in 139 (80%) patients: 76 (44%) 
refractory or relapsed disease, 63 (36%) untreated disease and 35 were in 
complete or partial remission of their HM.  
 
Efficacy of treatment in patients with fungemia 
Molds BSI  
Among 17 patients, 2 (12%) did not receive antifungal treatment, and both 
deceased of infection before identification of isolate and CVC removal. Treatment 
was performed with echinocandins in 7 (46%) patients, followed by L-AmphB in 
4 (27%) and various combination of two classes of antifungal agents in 4 (27%). 
Excluding untreated patients, we assessed an overall response rate of 33% (5 
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patients). CVC was removed after fungal isolation in 5 patients (33%): 3 deceased 
and 2 survived (both received a concomitant antifungal therapy).  
 
Yeasts non-Candida BSI 
Among 24 patients, 2 (8%) did not receive any antifungal treatment: 
identification of isolate succeeded death due to progression of HM in 1 patient 
and clinical improvement during mold active prophylaxis in another. Treatment 
was an echinocandin in 9 (41%) patients, followed by L-AmphB in 10 (45%) and 
other azoles in 3 (14%). Excluding untreated patients, we assessed an overall 
response rate of 50% (11 patients), even though a patient died of progression of 
its HM. CVC was removed after fungal isolation in 9 patients: 2 deceased and 7 
survived under concomitant antifungal therapy.  
 
Candidemia 
Among 174 patients, 18 (10%) did not receive antifungal treatment: 12 (71%) 
deceased before identification of isolate, in 7 cases due to infection and in 5 cases 
due to progression of HM. In 5 out of 6 patients (29%) who survived despite 
absence of antifungal therapy, CVC was removed after fungal isolation: only 3 
patients were receiving antifungal prophylaxis.  
Among 156 patients, treatment was an echinocandin in 81 (52%) of patients, 
followed by L-AmphB in 39 (25%) and fluconazole in 23 (15%). Four patients 
(3%) were treated with various combination of two classes of antifungal agents 
This article is protected by copyright. All rights reserved. 
while in 9 (5%) other azoles were used. Excluding untreated patients, we 
assessed an overall response rate of 63% (99 patients); 6/66 (9%) patients died 
of either progression of their HM or other complications. CVC was removed after 
fungal isolation in 83 patients: 19 deceased and 64 survived.  
 
Outcome of patients with fungemia 
Considering all 215 patients, overall mortality at 30 days was 41%: when 
considering only death directly related to fungemia, mortality rate lowered to 
21%. Progression of HM was reported as cause of death in 14%, and other causes 
were identified in 6% patients.  
Mortality rate largely varied when considering the isolates responsible of BSI. 
Molds overall mortality rate was 70% (attributable mortality, AM 53%), while 
yeasts overall mortality rate was 39% (AM 18%). When distinguishing Candida 
and other yeasts, we found an overall mortality rate of 38% (AM 17%) and of 
46% (AM 25%) respectively.  
 
Predictors of mortality in patients with fungemia 
At the univariate analysis, factors statistically associated with overall mortality 
were ECOG >2, use of steroids, chronic kidney impairment, GI and respiratory 
symptoms, signs of organ dissemination, septic shock and isolation of mold 
versus yeast, while recovery of neutropenia during therapy and removal of CVC 
were found to be protective (Table 3). 
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Sex, age, type and treatment of disease, occurrence of mucositis, diabetes, 
parenteral nutrition, chronic obstructive lung disease, previous fungal or 
bacterial infection, neutropenia at infection onset, duration of steroid therapy, 
insertion and type of CVC, type and duration of antifungal prophylaxis, fever, CVC 
related fungemia, isolation of Candida versus non-Candida strain were not 
statistically significant in univariate analysis.  
In multivariate analysis, only ECOG >2, septic shock and removal of CVC retained 
their statistically significance for overall mortality (Table 4).  
 
Predictors of mortality in the sub-group of patients with candidemia 
At the univariate analysis, factors statistically associated with overall mortality in 
174 patients with candidemia were ECOG >2, use of steroids, chronic kidney 
impairment, GI and respiratory symptoms, septic shock and concomitant 
bacterial sepsis, while isolation of C.albicans and removal of CVC were found to 
be protective (Table 3).  
Sex, age, type and treatment of disease, occurrence of mucositis, diabetes, 
parenteral nutrition, chronic obstructive lung disease, previous fungal or 
bacterial infection, neutropenia at infection onset, duration and recovery of 
neutropenia during therapy, duration of steroid therapy, insertion and type of 
CVC, type and duration of antifungal prophylaxis, fever, signs of organ 
dissemination, CVC related candidemia were not statistically significant in 
univariate analysis.  
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In multivariate analysis, ECOG >2 and removal of CVC retained their statistically 
significance for overall mortality (Table 4).  
 
DISCUSSION 
Over the past 25 years, several reports have been published focusing on 
characteristics and outcome of candidemia in patients with HMs (Table 5). Until 
1993, C. albicans was the main responsible of fungal BSI and fluconazole was 
consistently used as prophylaxis regimen. Since the broader use of mold active 
azoles, the epidemiology of Candida spp changed worldwide. A Northern America 
monocentric survey reported that 76% of yeast BSI were due to C. non albicans 
between 2001-2007 and up to 99% between 2008-2012 in a setting of antifungal 
prophylaxis with either mold active azoles or echinocandins and a high rate of 
breakthrough infection (72% and 94%, respectively) [7,8]. Lastly, a multicentric 
prospective survey recruiting patients in 13 centers among 8 countries between 
2005-2009 reported 59% of C. non albicans in HM patients, with a breakthrough 
rate of 30%2.  
Less is known about other fungi BSI among patients with HMs. In 2004, Lionakis 
addressed for the first time the clinical value of mold isolation from peripheral 
blood in cancer patients. At least a 20% of mold isolations were defined true BSI 
among patients with HMs as compared to none in solid tumor patients9. In a 
survey of immunocompromised patients with Scedosporium spp infection, 
fungemia was reported in 33% of recipients of HSCT and 66% of patients with 
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HMs10.  Fusarium spp was primarily detected in blood cultures in 28% of HSCT 
recipients with fusariosis3 and was associated with poor outcome. 
In our retrospective multicenter study, we identified 215 episodes of fungemia 
among 33 Italian tertiary care centers over a 6 year-surveillance. Unfortunately, 
neither data on the incidence of fungemia nor on the advantage of using a specific 
antifungal agent could be analyzed in the database. Similarly, data on empirical 
versus targeted therapy as well as on the timely removal of CVC are insufficient 
to draw any conclusion on the best approach. This survey provided useful 
information on the risk factors for fungemia and outcome on the basis of fungal 
isolation. 
Despite this study enrolled few patients, some observations can be made. Unlike 
the patients with a yeast infection, those with a mold infection showed a delay in 
recovering from neutropenia and tended to have dissemination to skin, lung or 
sinuses. Moreover, most cases were breakthrough fungemias, occurred in two 
third of cases receiving a mold active prophylaxis: in particular, six patients 
received posaconazole prophylaxis in this group. As for antifungal therapy, 
almost half of patients were treated with echinocandins and about one third with 
a combination of two antifungal drugs. Accordingly to the data of literature, also 
in our population mold BSI was associated with a poor outcome with a 70% 
overall mortality at 30 days.  
As previously reported8,11, we found that more than 80% of fungal BSI were 
detected in patients with active hematologic disease (refractory/relapsed or 
newly diagnosed HM): the underlying malignancy itself play a paramount role in 
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the development of IFI. Moreover, despite the median age of our population was 
not elevated, an ECOG performance status >2 was detected in 40% of patients. At 
univariate analysis, performance status >2, use of steroids, renal impairment, 
organ dissemination, signs of GI and respiratory failure, septic shock with 
multiorgan failure and isolation of molds were statistically associated to 
increased overall mortality. On the contrary, removal of CVC and recovery of 
neutropenia were protective factors for survival. In multivariate analysis, worse 
performance status, septic shock and removal of CVC emerged as prognostic 
factors for overall mortality. Unexpectedly, both overall and attributable 
mortality were not influenced by neutropenia itself rather than recovery of 
neutropenia, as the restored killing activity of granulocyte is of paramount 
importance against fungi infections. Removing CVC was helpful for the 
management of fungemia, even though a clear advantage of early versus late 
removal was not observed. Organ involvement and multiorgan failure syndrome 
are associated with fast worsening of clinical condition and dismal prognosis. 
Although antifungal prophylaxis has changed the epidemiology of fungal 
infections by reducing incidence of IFI, particularly mold infections, prophylaxis 
administration had no impact on survival, and none of antifungal drugs could 
demonstrate a superiority in respect of overall mortality. Hematological 
malignancy itself is the major risk for mortality: the rates of response to 
treatments widely vary according to the diseases. Moreover, in the registrative 
study of posaconazole in comparison with other azoles in the setting of 
prophylaxis of IFI during chemotherapy for AML and MDS, the authors 
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considered incidence of proven or probable IFI instead of mortality  as primary 
end point.  Indeed, starting antifungal therapy as soon as a fungal infection is 
suspected in high risk patient presenting with septic shock is strongly 
recommended as survival can be improved if fungemia is confirmed. A de-
escalation approach is always possible if a fungemia is not confirmed.  
C. albicans accounted for 34% of all Candida strains with no statistically 
significant differences among the centers. This is in line with other 
reports2,7,8,12,13 and it is probably a consequence of the use of antifungal 
prophylaxis, especially in patients with acute myeloid leukemia (AML) where 
Candida spp BSI are more frequently detected. As compared with the SEIFEM 
studies performed between 1999 and 2003, a statistically significant reduction in 
the incidence of candidemia was found (p= <0.0001, CI 1.41-1.73), particularly 
among patients with AML (from 4.1% to 1.5%, p= <0.001, CI 1.46-1.82). This was 
probably due to a wider use of posaconazole for antifungal prophylaxis in AML 
patients undergoing induction chemotherapy 14. 
Candidemia is associated usually with a good outcome due to the efficacy of the 
antifungal agents in managing Candida BSI compared to other yeasts and molds. 
Tending to confirm a decreasing mortality rates over the last years, our 
retrospective study showed a 38% overall and 17% attributable mortality at 30 
days (Table 5).  
In conclusion, fungemia remains a notable problem, due the high mortality rate, 
in hematological malignancies. A correct knowledge of epidemiology and of those 
parameters that can influence the outcome of this complication could be 
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extremely useful for a better personalized approach tailored to the needs and 
characteristics of each single patient.  
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Table 1. Characteristics of 215 patients with Fungemia
 
Molds (17) Candida spp (174) Other Yeasts (24)
Sex
Male 13 (76) 95 (55) 11 (46)
Female 4 (24) 79 (45) 13 (54)
Age (median) 52 (8-75) 56 (40-66) 61 (21-74)
         </=60 13 (76) 102 (59) 12 (50)
         >60 4 (24) 72 (41) 12 (50)
Haematological disease
         AML 8 (47) 73 (42) 15 (63)
         ALL 4 (24) 21 (12) 0
         NHL 1 (6) 51 (29) 5 (21)
         HL 0 3 (2) 0
         CML 3 (17) 1 (1) 1 (4)
         MM 0 13 (7) 1 (4)
         CLL 0 4 (2) 1 (4)
         MDS 1 (6) 8 (5) 1 (4)
Hsct (Yes/No) 1/16 (6) 55/119 (32) 3/21 (12)
         Autologous 0 19 (35) 0
         Allogeneic 1 (6) 36 (65) 3 (12)
Phase of disease
         Onset 5 (30) 63 (36) 9 (37)
         CR 0 25 (14) 4 (17)
         PR 0 10 (6) 0
         Resistance 3 (17) 38 (22) 5 (21)
         Recurrence 9 (53) 38 (22) 6 (25)
Central venous catheter 15 (88) 168 (96) 18 (75)
         PICC 7 (47) 56 (36) 10 (55)
         Central 8 (53) 99 (64) 8 (45)
ECOG >2 7 (41) 71 (41) 9 (37)
Risk Factors
         Parenteral nutrition 7 (41) 71 (41) 9 (37)
         Mucositis 4 (24) 57 (33) 9 (37)
         Surgical procedures 0 27 (15) 2 (8)
         Diabetes 4 (24) 18 (10) 3 (12)
         CKD 1 (6) 21 (12) 2 (8)
         COPD 2 (12) 6 (3) 0
Organ involvement 6 (35) 12 (7) 3 (12)
         Skin 2 (34) 7 (58) 1 (33)
         Lung 3 (50) 3 (25) 1 (33)
         Brain 0 3 (25) 0
         Sinuses 2 (34) 0 0
         Liver/Spleen 0 1 (8) 1 (33)
Neutropenia 15 (88) 134 (77) 23 (96)
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Recovery of neutropenia 2 (13) 47 (35) 5 (22)
Steroids 9 (50) 90 (52) 16 (67)
Clinical features
         Fever 17 (100) 171 (98) 24 (100)
         GI symptoms 2 (12) 56 (32) 7 (29)
         Respiratory symptoms 5 (29) 43 (25) 2 (8)
         Shock 3 (18) 24 (14) 2 (8)
Antifungal Prophylaxis 15 (88) 80 (46) 14 (58)
         Fluconazole 4 (27) 36 (45) 3 (21)
         Mold active 11 (73) 44 (55) 11 (79)
Therapy 15 (88) 157 (90) 22 (92)
         Ambisome 4 (27) 39 (25) 10 (45)
         Echinocandins 7 (46) 81 (52) 9 (41)
         Fluconazole 0 23 (15) 0
         Other azoles 0 9 (5) 3 (14)
         Combination therapy 4 (27) 4 (3) 0
Efficacy of therapy 5 (33) 99 (63) 11 (50)
Evolution
Death 12 (70) 66 (38) 11 (46)
Cause of death
         Infection 9 (53) 30 (17) 6 (25)
         Haematological disease 3 (17) 21 (13) 5 (21)
         Other 0 15 (8) 0
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Table 2. Distribution of all isolated strains 
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Table 3. Univariate analysis for overall mortality 
 ALL FUNGEMIE 
 
CANDIDEMIA 
 Odd’s ratio 
 
p-value Odd’s ratio p-value 
Performance Status 
>2 
 
4.75 
(2.53-8.91) 
0.00001 5.34 
(2.61 -10.97) 
0.00001 
Chronic kidney 
disease 
 
2.63 
(1.01-7.17) 
0.00259 2.44 
(0.87-6.98) 
0.0530 
Steroid 
administration 
 
2.11 
(1.16-3.85) 
0.0080 1.97 
(1.01-3.88) 
0.0319 
GI symptoms 
 
1.89 
(1.00-3.56) 
0.00325 1.88 
(0.93-3.79) 
0.0541 
Respiratory 
symptoms 
 
3.77 
(1.84-7.85) 
0.0001 4.56 
(2.07-10.21) 
0.00001 
Septic shock 
 
4.55 
(1.80-12.47) 
0.0003 4 
(1.48-11.47) 
0.0018 
Multiorgan failure 
 
2.63 
(1.01-7.17) 
0.00259   
Molds Vs Yeasts 
 
3.77 
(1.17-14.12) 
0.0109   
Concurrent bacterial 
sepsis 
 
  2.19 
(0.89-5.41) 
0.0562 
CVC removal 
 
0.27 
(0.14-0.53) 
0.00001 0.27 
(0.13- 0.56) 
0.0001 
Neutrophil recovery 
  
2.38 
(1.30-4.35) 
0.0023   
C. albicans vs. non-
albicans 
 
  0.25 
(0.12-0.51) 
0.0001 
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Table 4. Multivariate analysis for overall mortality 
 ALL FUNGEMIE 
 
CANDIDEMIA 
 Odd’s ratio 
 
p-value Odd’s ratio p-value 
Performance Status 
>2 
 
4.33 
(2.24- 8.37) 
0.00001 4.29 
(2.06- 8.91) 
0.00001 
Shock 
 
2.71 
(1.16-3.85) 
0.042   
CVC removal 
 
0.41 
(0.21-0.80) 
0.010 0.39 
(0.18-0.81) 
0.013 
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Table 5. Studies on candidemia in patients with HMs over the last 30 years 
 
 
 
Period of observation
Number of 
patients
Incidence
Breakthrough 
rate
Candida non 
albicans isolates 
Overall mortality 
(30 days)
Attributable 
mortality (30 days)
Pagano Eur J 
Hematol 1999 
1988-1997 76 _ 86% 70% 49% 26%
Viscoli CID 1999 1992-1994 150 _ 40% 64% 39% 24%
Pagano 
Haematologica 2006
1999-2003 175 1.5 _ 57% _ 33%
Sipsas Cancer 2009 2001-2007 170 _ 72% 76% 68% 19%
Horn Clin Inf Dis 
2009
2004-2008
2019 (all cause 
hospitalization)
_ 43% 54.4% 35.2% at 12 weeks _
Zirkel Med Mycol 
2012
2003-2009 21 (14 HM)
1.4/1000 
hospitalization
25% 72% 56% _
Chen Int J 
Antimicrob Agents 
2012
2001-2010 111 4.3% _ 68.4% 31.5% _
Bergamasco 
Mycoses 2013
2003-2007 117 _ 46% 69% 54%
Cornely CID 2015 2005-2009
140 (HM and 
cancer)
0.19% 32.8% 59% 35% 72% at 2 weeks
Gedik Therapeutics 
and Clinical Risk 
Management 2014
2010-2012 18 _ _ _ 16.6% _
Gamaletsou Clin 
Microb Inf 2014
2009-2012 40 1.4/1000 53% 87,50% 45% 27,50%
Dewan Hem Onc 
Stem Cell 2015
2010-2012
150 (both adults 
and pediatrics)
_ _ 73.3% _ _
Puig-Asensio Clin 
Microb Inf 2015
2010-2011 43 _ 46.5% 71.1% 30.2% _
Wang J Antimicrob 
Chemother 2015
2008-2012 65 _ 94% 99% 52% _
Lortholary Intensive 
Care Med 2017
2002-2014 586 _ 20.6% 51.5% 35.6% _
Present study                                    2011-2015 174 _ 46% 66.6% 38% 17%
